Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Cellebrite DI (CLBT) Shares Outstanding (2019 - 2025)

Cellebrite DI's Shares Outstanding history spans 7 years, with the latest figure at $248.6 million for Q4 2025.

  • Quarterly Shares Outstanding rose 5.99% to $248.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $248.6 million through Dec 2025, up 5.99% year-over-year, with the annual reading at $248.6 million for FY2025, 5.99% up from the prior year.
  • Shares Outstanding came in at $248.6 million for Q4 2025, up from $234.5 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $248.6 million in Q4 2025 to a low of $187.7 million in Q4 2021.
  • The 5-year median for Shares Outstanding is $203.2 million (2023), against an average of $213.4 million.
  • Year-over-year, Shares Outstanding skyrocketed 50.54% in 2021 and then rose 2.84% in 2022.
  • Cellebrite DI's Shares Outstanding stood at $187.7 million in 2021, then rose by 2.84% to $193.0 million in 2022, then grew by 5.29% to $203.2 million in 2023, then increased by 15.4% to $234.5 million in 2024, then increased by 5.99% to $248.6 million in 2025.
  • Per Business Quant, the three most recent readings for CLBT's Shares Outstanding are $248.6 million (Q4 2025), $234.5 million (Q4 2024), and $203.2 million (Q4 2023).